R-Pharm out-licenses molecule for design of anti-cancer drugs to Aspyrian

29 July 2017

R-Pharm, one of Russia’s leading drugmakers, has signed an agreement with the USA’s clinical stage biotech firm Aspyrian Therapeutics on the transfer of the rights for the use of one of its investigational molecules by the US company during the development of anti-cancer drugs, reports The Pharma Letter’s local correspondent.

Financial details of the deal are not disclosed. Under the terms of the agreement, Aspyrian, which currently specializes on the development of target antitumor drugs, will pay R-Pharm royalties from the use of its molecule in the US market.

According to Vasily Ignatiev, general director of R-Pharm, currently the molecule is in the second phase of clinical trials. According to him, this is a bio-analogue of cetuximab, the main purpose of which is treatment of squamous cell carcinoma of head and neck. At the same time there is also a possibility that the drug will be used for the treatment of other cancer localizations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK